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Introduction
Decitabine is a cytosine analog with S- phase- dependent 
pharmacokinetics that is incorporated into DNA, but can-
not be methylated [1–3]. Historically, it has yielded clinical 
responses in ~25% of patients with acute myeloid leukemia 
(AML) or myelodysplastic syndromes (MDS) across diverse 
clinical trials, although response rates may be higher using 
a 10- day versus 5- day approach [4–6]. In general, 
decitabine is well tolerated and can be given in the out-
patient setting.
Decitabine treatment is associated with infection com-
plications and readmission for neutropenic fevers [5, 7, 
8]. Limited data exist concerning the types of infections 
that occur in AML and MDS patients treated with 
decitabine.
We recently completed a study of AML and MDS 
patients treated with decitabine administered in 10 daily 
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Abstract
Decitabine has been explored as a reduced- intensity therapy for older or unfit 
patients with acute myeloid leukemia (AML). To better understand the risk of 
infections during decitabine treatment, we retrospectively examined the culture 
results from each infection- related serious adverse event that occurred among 
85 AML and myelodysplastic syndromes (MDS) patients treated in a prospective 
clinical study using 10- day cycles of decitabine at Washington University School 
of Medicine. Culture results were available for 163 infection- related complica-
tions that occurred in 70 patients: 90 (55.2%) events were culture- negative, 32 
(19.6%) were gram- positive bacteria, 20 (12.3%) were gram- negative bacteria, 
12 (7.4%) were mixed, 6 (3.7%) were viral, 2 (1.2%) were fungal, and 1 (0.6%) 
was mycobacterial. Infection- related mortality occurred in 3/24 (13%) of gram- 
negative events, and 0/51 gram- positive events. On average, nearly one third of 
patients experienced an infection- related complication with each cycle, and the 
incidence did not decrease during later cycles. In summary, in patients receiving 
10- day decitabine, infectious complications are common and may occur during 
any cycle of therapy. Although febrile events are commonly culture- negative, 
gram- positive infections are the most frequent source of culture- positive infec-
tions, but gram- negative infections represent a significant risk of mortality in 
AML and MDS patients treated with decitabine.
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doses per cycle [5]. Similar to others [6], we observed 
modestly higher response rates using the 10- day regimen 
(46%) versus published results from 5- day regimens 
(17–32%) [8–11], and the majority of Common 
Terminology Criteria for Adverse Events (CTCAE)- defined 
significant adverse events (SAEs) we observed were associ-
ated with infectious complications and readmission for 
neutropenic fevers [5]. We also observed that response 
correlated with the presence of mutations in TP53 [5].
Antibiotic prophylaxis has been controversial during 
AML chemotherapy (for both decitabine and cytarabine- 
based treatments), and the benefits of prophylaxis are 
unclear.
In this study, we reviewed each infection- related SAE 
observed among 85 patients to determine whether the 
infectious complications observed during decitabine treat-
ment might be different from the complications of more 
intensive regimens, and whether specific bacteria were 
commonly observed that might be amenable to alternative 
prophylaxis.
Patients and Methods
Study design
We reviewed all CTCAE (version 4.0) grade 3–5 SAEs 
associated with infectious complications in 85 patients 
with AML or MDS who were enrolled between April 2013 
and November 2015 on a clinical study at Washington 
University School of Medicine (NCT01687400) [5]. Of 
these, 70 patients had infection- related events with docu-
mented culture results that could be retrospectively evalu-
ated. This study was approved by our institutional review 
board and conducted in accordance with the provisions 
of the Declaration of Helsinki. Response evaluation and 
molecular end- points have been previously published [5].
Treatment
Decitabine was administered intravenously at a dose of 
20 mg/m2 of body surface area per day in 28- day cycles. 
Initial cycles were given on consecutive days 1–10. Once 
patients achieved blasts <5%, they could reduce the dos-
ing to days 1–5. After two cycles with dosing on days 
1–5, the dose could be reduced further to days 1–3.
Antimicrobial therapy
Prophylactic antimicrobial therapy was recommended, but 
not stipulated as part of the study. Recommended prophy-
laxis consisted of acyclovir, ciprofloxacin, and fluconazole. 
Patients who developed infection- related complications 
were treated with antimicrobial and supportive therapy 
according to commonly accepted guidelines. The diagnostic 
work- up in case of fever included collection of blood 
cultures from central venous catheters and peripheral vein 
and collection of nasal, pharyngeal, and anal swab. Standard 
chest radiographs were obtained at hospital admission and 
if clinically indicated. Cytomegalovirus (CMV) reactivation 
was not routinely tested. Prompt empiric first- line therapies 
consisted of cephalosporin, penicillin, or carbapenem anti-
biotics. Vancomycin was added if fever persisted for 
48–72 h and at least one of the following clinical findings 
was met: clinically suspected serious catheter- related infec-
tions, known colonization with penicillin- and 
cephalosporin- resistant pneumococci or methicillin- 
resistant Staphylococcus aureus, positive blood cultures 
for gram- positive bacteria before the final identification, 
hypotension or other evidence of cardiovascular impair-
ment. An azole or echinocandin was given empirically if 
the patient did not respond to antibiotic therapy within 
5–7 days. Modifications of the antibiotic therapy were 
made on the basis of results of cultures and susceptibili-
ties of microorganisms to antimicrobial agents.
Assessment of infection incidence and 
outcome
Each recorded infection- related serious adverse event was 
reviewed. Fever was considered as a single temperature 
measurement of 38.4°C or 38.0°C over at least 1 h, in 
the absence of obvious environmental causes.
Neutropenia was defined as an absolute neutrophil count 
(ANC) less than 1.0 × 109/L. ANC was further categorized 
according to whether they were <0.5 × 109/L or 
<0.1 × 109/L at the onset of febrile episodes.
The causative agent, when identified, was classified as 
bacterial (gram- positive, gram- negative, or mycobacterial), 
fungal (Candida species, Aspergillus species, or other), or 
viral (varicella zoster virus, herpes simplex virus [HSV]).
The site of infection was classified as blood (bacteremia), 
skin and/or soft tissues, catheter- related blood stream 
infection, gastrointestinal (GI) tract, upper respiratory tract 
(pharyngitis, sinusitis, rhinitis), lower respiratory tract 
(pneumonia or bronchitis), urinary tract or joint/bone 
(septic arthritis, osteomyelitis).
The outcome of infections for each patient was deter-
mined at the completion of the antimicrobial therapy. All 
patients who died of infection were considered a failure.
Statistical analysis
Data were analyzed through November 2016. Statistical 
analysis was performed using SPSS program, version 24 
(IBM, Chicago, IL). Univariate analysis (Fisher exact test 
and Pearson chi- square T- test) was used for assessment 
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of infection incidence. P < 0.05 was considered statisti-
cally significant. The distribution of overall survival was 
described using Kaplan–Meier curves and compared by 
log- rank test. Survival analysis was performed using Prism 
5 (GraphPad, San Diego, CA).
Results
Patients
A total number of 282 cycles of decitabine were admin-
istered to 85 patients with AML or MDS (Table 1). Fifty 
patients were males (58.8%) and 35 were females (41.2%). 
The median age of the patient population was 74 years 
(range: 31–89 years). The median number of cycles received 
was 2 (range 0.5–17). Two hundred and forty- eight hos-
pital admissions following the administration of decitabine 
were reviewed. Of these admissions, 65.7% were for febrile 
episodes or infections (total of 163 admissions). The 30- 
day mortality was 2.4%, the 60- day mortality was 19%, 
and the 6- month survival was 63.5%. The clinical features 
of patients with and without infection- related events are 
shown in Table 1.
Effect of clinical factors
Clinical features were correlated with the incidence of 
infection- related SAEs (gender, age, performance status, 
disease, response, and cycles completed). The median and 
the mode number of infection- related SAEs per patient 
in each subgroup was 1 (Table 1).
The incidence of infection- related SAEs was correlated 
with the cycle number (Fig. 1A). On average, within each 
cycle, approximately one third of patients receiving that 
cycle experienced an infection- related SAE, and we observed 
no consistent reduction in incidence during higher num-
bered cycles (i.e., cycles 4–9). Overall, the median survival 
of the cohort was 318 days. Counterintuitively, patients 
without an infection- related SAE had shorter survival 
(median 104 days vs. 446, 354, and 318 days for patients 
with 0, 1, 2, or 3 or more SAEs, respectively), perhaps 
because they did not remain on therapy long enough to 
experience a complication (Fig. 1B).
In a univariate analysis comparing patients who had no 
infections versus those who had one or more, patients with 
younger age (age <70) tended to have a higher incidence 
of infections. However, older patients had shorter survival, 
and this may account for the disproportionate number of 
older patients without an infection- related event (Fig. 1C). 
Nevertheless, the difference in infection incidence between 
the two groups (>70 vs. <70) did not reach a statistical 
significance (P = 0.129). Likewise, compared to infections 
incidence in AML patients (77.5%), a higher incidence of 
infections was noted in MDS patients (96.3%, P = 0.032). 
However, AML patients also had shorter survival compared 
with MDS patients (Fig. 1D). Therefore, patients who lived 
longer and had more therapy tended to have more infec-
tion episodes, although developing multiple infections did 
not affect the overall survival compared to patients who 
only experienced one or two infections (Fig. 1B).
Blood count results were prospectively recorded on day 
0, cycle 1 day 10 (C1D10), cycle 1 day 28 (C1D28), and 
at the end of even cycles. Neutropenia was common across 
all time- points (Fig. 1E). In total, 23%, 60%, and 69% 
of patients had an ANC <0.1, <0.5, and <1.0 at two or 
more measurements, respectively. At the time of each 
infection- related SAE, the ANC was retrospectively assessed. 
The majority of patients had neutropenia with ANC 
<1.0 × 109/L (88.6%), or ANC <0.5 × 109/L (83%) at 
the onset of infection, and more than half of the patients 
(60.3%) presented with ANC <0.1 × 109/L (Fig. 1F).
For each event, the recorded admission for antibacterial, 
antiviral, and antifungal prophylactic agents were reviewed 
(Table 2). In the majority of admissions (74.8%, 122 of 
163), the patients were documented as receiving antiviral 
Table 1. Clinical data.
Characteristic Number of infection- related SAEs Totals
0 1 2 >2
Gender
Male 12 18 8 12 50
Female 2 16 8 9 35
Age
<40 0 1 0 1 2
40–60 0 4 2 1 7
>60 14 29 14 19 76
Performance status
0 5 11 6 4 26
1 5 13 9 13 40
2 4 9 1 4 18
Unknown 0 1 0 0 1
Disease
AML 13 19 11 15 58
MDS 1 15 5 6 27
Response
CR 2 4 1 2 9
CRi/mCR 5 13 8 10 36
PR/SD/PD 3 11 5 8 27
Not evaluable 4 6 2 1 13
Cycles completed
<1 4 4 2 1 11
1 2 8 3 2 15
2 4 8 6 4 22
3 0 4 3 4 11
>3 4 10 2 10 26
Total 14 34 16 21 85
AML, acute myeloid leukemia; MDS, myelodysplastic syndromes; SAEs, 
significant adverse events.
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prophylaxis. Fewer patients were documented as receiving 
antibacterial (54%) or antifungal prophylaxis (41.7%). Of 
the admissions where patients were already receiving 
antibacterial prophylaxis, only 30% (27 of 90) had posi-
tive cultures for bacteria. In contrast, positive cultures 
were noted in 42.8% (33 of 77) of the admissions of 
patients with no antibacterial prophylaxis (P value: 0.08). 
Furthermore, two of the six positive cultures for fungi 
occurred in the setting of antifungal prophylaxis and five 
of the eight viral infections occurred in patients receiving 
antiviral prophylaxis (parainfluenza, HSV and rhinovirus/
enterovirus).
Causative agent
In 55.2% of the admissions (90 of 163), a clinically suspected 
infection was associated with negative culture results. A 
Figure 1. Correlation of infection events with clinical features. (A) The incidence of infection- related events occurring within each cycle of therapy, 
restricted to cycle numbers received by at least five patients. (B) Overall survival correlation with the number of infection- related SAEs a patient 
experienced during therapy. (C and D) Correlation of age and disease with overall survival. P values indicate results of log- rank test. (E and F) Absolute 
neutrophil count (ANC) at the schedule bone marrow biopsies and at the time of infection- related SAEs (ANC values indicate 109 neutrophils per liter).
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Table 2. Prophylaxis at the time of infection.
Prophylaxis Number 
events
Class of 
prophylaxis
Totals
Ciprofloxacin 74 Total antibiotics 88 (54%)
Other antibiotics 14
Acyclovir 101 Total antivirals 122 (74.8%)
Other antivirals 21
Fluconazole 51 Total antifungals 68 (41.7%)
Other antifungal 17
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causative agent of infection was documented in 73 (44.8%) 
of 163 admissions: gram- positive infections in 32 (19.6% of 
total admissions), 20 (12.3%) were gram- negative, 12 (7.4%) 
of admissions were associated with mixed infections (two 
or more different pathogens), 6 (3.7%) were viral, two (1.2%) 
were fungal, and 1 (0.6%) was mycobacterial. A total number 
of 91 pathogens were retrieved from the infectious diagnostic 
workups (cultures, swabs, etc. that were performed in these 
73 admissions) (Table 3). Gram- positive bacteria represented 
56% of the total isolated pathogens: coagulase- negative staphy-
lococci including Staphylococcus epidermidis represented the 
most common gram- positive organisms (23/91: 25.3%) fol-
lowed by vancomycin- resistant enterococcus (VRE) (10/91: 
11%). Pseudomonas species (8/91: 8.8%) followed by 
Escherichia coli (6/91: 6.6%) were the most frequent gram- 
negative pathogens. In the study population, 6 (6.6%) and 
8 (8.8%) of the microbiology- documented infections were 
caused by fungal and viral agents respectively.
Site of infection
Lower respiratory tract infections were the most common 
site for infection (28 events: 17.2% of all admissions). 
This was followed by bacteremia (27 events: 16.6% of all 
admissions) (Table 4).
Type of catheter
To understand whether indwelling catheters might influ-
ence the frequency and types of infections, we reviewed 
admission chest X- rays and procedure notes associated 
with all 163 hospitalizations. In 101 of the 163 hospitali-
zations (62%), the patients had a central venous catheter 
(Hohn). Twenty (12%) had implanted port, 20 (12%) 
had peripherally inserted central catheters (PICC), and 
22 (14%) had peripheral access. Patients who had Hohn 
or PICC catheters tended to have more gram- positive 
infections compared to patients with other types of access 
(port and peripheral access). However, this correlation 
did not reach statistical significance (P = 0.47).
Infection susceptibility
Of the gram- positive organisms identified, vancomycin and 
linezolid were most frequently associated with susceptibility. 
In contrast, gram- negative organisms were most frequently 
susceptible to cefepime, meropenem, and gentamycin. 
Cefepime and vancomycin were the most commonly used 
empiric antibiotics overall (56.25% of the admissions). Ten 
of the Enterococcus cases (out of 12: 83.3%) were VRE. 
Two of the Staphylococcus cases (out of 25: 8%) were 
methicillin resistant (MRSA). One of the E. coli infections 
was caused by extended- spectrum beta- lactamase 
(ESBL)- producing organism. A prophylactic antibacterial 
(ciprofloxacin 500 BID) was being administrated in five 
cases (38.5%) of the 13 cases of resistant microorganisms 
(MRSA, VRE, and ESBL) prior to admission. All the 
Pseudomonas infections were sensitive to carbapenems.
Table 3. Causative agent associated with infection.
Infection Events Totals (%)
Gram- positive 51/91 (56)
MRSA 2
Coagulase- negative staph
Staphylococcus epidermidis 8
Others 15
Enterococcus
Vancomycin- sensitive 2
Vancomycin- resistant 10
Other
Viridans group 4
Corynebacterium 5
Lactobacillus 2
Clostridium difficile 3
Gram- negative 24/91 (26.4)
Pseudomonas 8
Escherichia coli 6
Enterobacteriaceae 2
Stenotrophomonas 4
B. fragilis 1
Achromobacter 1
Citrobacter 2
Mycobacteria 2/91 (2.2)
M. gordonae 1
Mycobacterium abscessus 1
Fungus 6/91 (6.6)
Candida 2
Aspergillus 1
Mucor 1
Fusarium 1
Curvularia 1
Viruses 8/91 (9)
Rhinovirus/enterovirus 3
Parainfluenza virus 2
HSV 1
Adenovirus 1
Coronavirus 1
MRSA, methicillin resistant; HSV, herpes simplex virus.
Table 4. Site of infection.
Site Events Percent of 
admissions
Lower respiratory 28 17%
Peripheral blood 26 16%
Central line 27 16.5%
Wound or soft tissues 14 9%
GI 7 4.2%
Upper respiratory 6 4%
Urinary 3 1.8%
GI, gastrointestinal.
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Infection outcome
Complete recovery from infectious complications was 
observed in the majority of patients. The patients were 
discharged on a prophylactic antibiotic (ciprofloxacin 
500 mg BID) in 37.5% of the admissions. The length of 
prophylaxis was indefinite in almost half of these cases.
During the study period, 10 (31.2%) of the gram- positive 
and 3 (15%) of the gram- negative infections required read-
mission within 6 weeks. A total of seven deaths were attributed 
to infection- related complications, with an overall incidence 
of 8.2% (7 of 85 patients). Three deaths were due to gram- 
negative bacteremia/sepsis (caused by Pseudomonas and ESBL- 
producing E. coli), two due to pneumonia and acute respiratory 
failure, one due to mixed bacteremia (Mycobacterium abscessus 
and VRE), and one due to pneumonia associated with dis-
seminated fusarium. Only one of these seven cases was on 
prophylactic antibiotics prior to admission.
Effect of quinolone prophylaxis
Patients who were receiving quinolone prophylaxis at the 
time of the SAE tended to have fewer positive cultures 
compared to those who were not receiving prophylaxis (43% 
vs. 57%); although this did not reach a statistical significance 
(P = 0.084). The presence of antibiotics prophylaxis at the 
time of admission was not associated with statistically sig-
nificant higher rates of resistant microorganisms (P = 0.087) 
or lower rates of mortality (P = 0.705). Two of the cases 
of Clostridium difficile colitis occurred in the setting of 
prophylactic ciprofloxacin treatment, and one did not.
Discussion
Relatively few precise data are available on the incidence 
and characteristics of bacterial, fungal, and viral causes 
of infections in AML and MDS patients treated with 
decitabine [12, 13]. In this study, we investigated retro-
spectively the infectious complications that occurred in 
85 patients with AML or MDS enrolled in NCT01687400. 
In this study, we have described the prevalence and char-
acteristics of clinically and microbiologically defined infec-
tions and infection- related mortality, and the relationship 
between number of cycles and infection- related events as 
well as the effect of prophylaxis on the positivity of cul-
tures and susceptibility of microorganisms.
Neutropenia was common across all cycles of therapy 
(Fig. 1E). Based on the frequency and duration of neu-
tropenia observed in this cohort, current guidelines would 
recommend consistent quinolone prophylaxis and con-
sideration of antifungal prophylaxis [14, 15].
Infection- related grade 3–5 SAEs occurred in 70 of 85 
patients (82%) during therapy, and were observed in 
approximately one third of patients during each cycle. 
When compared to the incidence of infections when using 
a 5- day decitabine regimen (29%) [9], longer courses of 
therapy (10- day) were associated with more infections: 82% 
in this study and 68% reported by Blum et al. [6]. However, 
30- day mortality and 6- month survival remained compa-
rable (2.4% vs. 7% and 63.5% vs. 60% in this cohort and 
a cohort treated with the 5- day regimen, respectively) [9].
Fever and infections were the most frequent cause of 
hospitalization in our patient population. The majority of 
these events were not associated with a causative agent; an 
identifiable organism was isolated in 45% of admissions 
and bacteria represented the most commonly identified 
source of infection. Microbiologically or clinically docu-
mented fungal or viral infections were diagnosed in less 
than 5% of hospitalizations. In our study, the ratio of 
gram- positive to gram- negative bacteria approached 2:1. 
Gram- positive cocci (predominantly coagulase- negative 
staphylococci) represented the most frequently isolated 
microorganisms. This finding is not surprising, and consist-
ent with the literature of other chemotherapeutic agents 
in hematological malignancies as well as solid cancers [16, 
17]. This dominant gram- positive pattern can be attributed 
to the widespread use of indwelling intravascular catheters 
and the use of prophylaxis targeted against gram- negative 
organisms (e.g., ciprofloxacin). Surgically implanted tunneled 
catheters have been associated with lower rates of blood-
stream infections than percutaneously inserted catheters [18, 
19]. In this study, we observed a nonsignificant trend toward 
greater numbers of gram- positive infections in patients with 
Hohn and PICC catheters, as might be expected. AML 
and MDS patients receiving decitabine frequently present 
with cytopenias and are unable to obtain a surgically 
implanted catheter until they achieve remission. This limits 
this opportunity for alternative access, and physicians should 
be cognizant of the risks and opportunities posed by dif-
ferent forms of percutaneous access. Enterococcal species, 
especially vancomycin- resistant bacteria, represented the 
second most common gram- positive isolates in our popula-
tion, causing mainly bacteremia and urinary tract infections. 
Nevertheless, the rate of VRE infections appears to be similar 
in our patients compared to patients undergoing induction 
with more intensive chemotherapy (11% compared to 10%) 
[20, 21]. Although colonization is far more frequent than 
true infection even in immunocompromised patients, bac-
teremia with VRE has been involved in outbreaks among 
oncology patients treated with chemotherapy and can be 
associated with increased mortality rates [20, 22].
Viridans group streptococci are other important pathogens 
that are classically seen in patients undergoing induction 
with high- dose intensive chemotherapy associated with neu-
tropenia and oropharyngeal mucositis [23–26]. Four cases 
of this type of bacteremia have been isolated in our patient 
2820 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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group (2.5%). Only one case had mucositis (rare with decit-
abine) at the time of bacteremia. Therefore, other ports of 
entry, such as GI mucosa or central venous lines, may rep-
resent potential sources for these infections in these patients.
Infection- related mortality in our cohort was associated 
with gram- negative bacteremia, pneumonia, and one case 
of disseminated Fusarium. These data are consistent with 
historical outcomes of aerobic gram- negative bacilli (E. coli 
and Pseudomonas aeruginosa) [27, 28], and the focus of 
our antibacterial prophylaxis targeted these bacteria. 
Primary prophylaxis with fluoroquinolones in our patient 
population was associated with a trend toward fewer posi-
tive blood cultures (P = 0.084), but was not associated 
with higher rates of resistant microorganisms or lower 
rates of mortality.
Fungal infections are an infrequent, but recurrent cause 
of morbidity and mortality. We observed an incidence 
of probable/proven invasive fungal infections of 7% includ-
ing the mixed infections. Although the spectrum of the 
fungal pathogens is similar (commonly, Aspergillus species 
and Candida species), the incidence may be modestly 
lower than the reported 12% incidence rate of IFIs in 
AML patient treated with more intensive cytotoxic therapy 
[29]. Nevertheless, considering the high number of observed 
clinically suspected infections with negative cultures, we 
cannot exclude that the incidence of invasive fungal infec-
tions might be higher.
Similar patterns of infectious complications have been 
reported in AML patients during intensive chemotherapy. 
A review of 747 adults with AML treated with conven-
tional chemotherapy identified a source organism in 56.6% 
of the febrile episodes [30]. Although bacterial infections 
were also the most frequent cause of infectious complica-
tions (38.4%), more gram- negative infections were observed 
(ratio 1:1), and a modestly higher incidence of fungal 
infections was observed (13.8%) [29, 30].
In sum, we found that infection- related SAEs were 
common in AML and MDS patients undergoing a 10- 
day decitabine regimen. In this cohort, admission to the 
hospital for evaluation of neutropenic fever occurred in 
the majority of patients at some point during treatment, 
and occurred in nearly one third of patients during each 
cycle of treatment. A causative agent was identified in 
less than half of admissions, and gram- positive bacteria 
were the most frequent agents identified. However, gram- 
negative infections were associated with mortality. 
Although expanding antimicrobial prophylaxis to include 
better gram- positive coverage (e.g., ampicillin or aug-
mentin) could reduce the incidence of hospital admis-
sions, this is unlikely to have an impact on overall survival. 
Furthermore, the downsides of this approach including 
toxicities and the potential for promoting resistance should 
be considered. Prospective studies are needed to determine 
whether the benefit of antibacterial prophylaxis outweighs 
the risks.
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